The Biochemistry, Physiology and Pathological roles of PAI-1 and the requirements for PAI-1 inhibition in vivo

Thrombosis Research

Volumn 130, Issue 4, 2012, Pages 576-585

  Van De Craen, Britt ^a   Declerck, Paul J ^a   Gils, Ann ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOLYTIC AGENT; MONOCLONAL ANTIBODY; PLASMIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 1 ANTIBODY; S 35225; SODIUM CHLORIDE; TIPLASININ; TISSUE PLASMINOGEN ACTIVATOR; TM 5275; UNCLASSIFIED DRUG; VITRONECTIN; XR 11211; XR 5118;

ADIPOSE TISSUE; BLOOD CLOT LYSIS; CANCER GROWTH; CARBOXY TERMINAL SEQUENCE; CARDIOVASCULAR DISEASE; CRYSTAL STRUCTURE; ENZYME ACTIVITY; ENZYME SPECIFICITY; FIBRINOLYSIS; GENETIC POLYMORPHISM; HUMAN; IC 50; IN VIVO STUDY; MOLECULAR CLONING; MUTAGENESIS; NEOPLASM; NONHUMAN; NUCLEOTIDE SEQUENCE; OBESITY; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; PROTEIN STABILITY; PROTEIN STRUCTURE; PROTEIN SYNTHESIS INHIBITION; PROTEIN TARGETING; REVIEW; SPECIES DIFFERENCE; THERMOSTABILITY;

ANIMALS; CARDIOVASCULAR DISEASES; DRUG DISCOVERY; FIBRINOLYSIS; GENE EXPRESSION REGULATION; HUMANS; METABOLIC DISEASES; MOLECULAR TARGETED THERAPY; NEOPLASMS; PLASMINOGEN ACTIVATOR INHIBITOR 1; VITRONECTIN;

EID: 84866235383     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2012.06.023     Document Type: Review

References (165)

1. D.C. Rijken, and H.R. Lijnen New insights into the molecular mechanisms of the fibrinolytic system J Thromb Haemost 7 1 2009 4 13
2. H.R. Lijnen, and D. Collen Matrix metalloproteinase system deficiencies and matrix degradation Thromb Haemost 82 2 1999 837 845
3. L. Polgar The catalytic triad of serine peptidases Cell Mol Life Sci 62 19-20 2005 2161 2172
4. P.B. Coughlin Antiplasmin - The forgotten serpin? FEBS J 272 19 2005 4852 4857
5. C. Dellas, and D.J. Loskutoff Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease Thromb Haemost 93 4 2005 631 640
6. J.L. Willemse, E. Heylen, M.E. Nesheim, and D.F. Hendriks Carboxypeptidase U (TAFIa): a new drug target for fibrinolytic therapy? J Thromb Haemost 7 12 2009 1962 1971
7. D.J. Loskutoff, J.A. Vanmourik, L.A. Erickson, and D. Lawrence Detection of an unusually stable fibrinolytic inhibitor produced by bovine endothelial cells Proc Natl Acad Sci U S A 80 10 1983 2956 2960
8. A.J. Simpson, N.A. Booth, N.R. Moore, and B. Bennett Distribution of plasminogen activator inhibitor (PAI-1) in tissues J Clin Pathol 44 2 1991 139 143
9. N.A. Booth, A.J. Simpson, A. Croll, B. Bennett, and I.R. Macgregor Plasminogen activator inhibitor (PAI-1) in plasma and platelets Br J Haematol 70 3 1988 327 333
10. E.K.O. Kruithof, G. Nicolosa, and F. Bachmann Plasminogen activator inhibitor-1 - development of a radioimmunoassay and observations on its plasma concentration during venous occlusion and after platelet aggregation Blood 70 5 1987 1645 1653
11. H. Brogren, L. Karlsson, M. Andersson, L.W. Wang, D. Erlinge, and S. Jern Platelets synthesize large amounts of active plasminogen activator inhibitor 1 Blood 104 13 2004 3943 3948
12. H. Brogren, K. Wallmark, J. Deinum, L. Karlsson, and S. Jern Platelets retain high levels of active plasminogen activator inhibitor 1 PLoS One 6 11 2011 e26762
13. H. Pannekoek, H. Veerman, H. Lambers, P. Diergaarde, C.L. Verweij, and A.J. Vanzonneveld Endothelial plasminogen activator inhibitor (PAI): a new member of the Serpin gene family EMBO J 5 10 1986 2539 2544
14. T. Ny, M. Sawdey, D. Lawrence, J.L. Millan, and D.J. Loskutoff Cloning and sequence of a cDNA coding for the human beta-migrating endothelial cell type plasminogen activator inhibitor Proc Natl Acad Sci U S A 83 18 1986 6776 6780
15. D. Ginsburg, R. Zeheb, A.Y. Yang, U.M. Rafferty, P.A. Andreasen, and L. Nielsen cDNA cloning of human plasminogen activator inhibitor from endothelial cells J Clin Invest 78 6 1986 1673 1680
16. P.A. Andreasen, A. Riccio, K.G. Welinder, R. Douglas, R. Sartorio, and L.S. Nielsen Plasminogen activator inhibitor type-1 - Reactive center and amino-terminal heterogeneity determined by protein and cDNA sequencing FEBS Lett 209 2 1986 213 218
17. D.J. Loskutoff, M. Linders, J. Keijer, H. Veerman, H. Vanheerikhuizen, and H. Pannekoek Structure of the human plasminogen activator inhibitor-1 gene - nonrandom distribution of introns Biochemistry 26 13 1987 3763 3768
18. J.P. Irigoyen, P. Munoz-Canoves, L. Montero, M. Koziczak, and Y. Nagamine The plasminogen activator system: biology and regulation Cell Mol Life Sci 56 1-2 1999 104 132
19. A. Gils, and P.J. Declerck The structural basis for the pathophysiological relevance of PAl-l in cardiovascular diseases and the development of potential PAl-l inhibitors Thromb Haemost 91 3 2004 425 437
20. R.H.P. Law, Q.W. Zhang, S. McGowan, A.M. Buckle, G.A. Silverman, and W. Wong An overview of the serpin superfamily Genome Biol 7 5 2006 216
21. J.A. Huntington, R.J. Read, and R.W. Carrell Structure of a serpin-protease complex shows inhibition by deformation Nature 407 6806 2000 923 926
22. C.M. Hekman, and D.J. Loskutoff Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants J Biol Chem 260 21 1985 1581 1587
23. P.J. Declerck, M. Demol, D.E. Vaughan, and D. Collen Identification of a conformationally distinct form of plasminogen activator inhibitor-1, acting as a noninhibitory substrate for tissue-type plasminogen activator J Biol Chem 267 17 1992 11693 11696
24. T. Urano, L. Strandberg, L.B.A. Johansson, and T. Ny A substrate-like form of plasminogen activator inhibitor type 1 - Conversion between different forms by sodium dodecyl sulfate Eur J Biochem 209 3 1992 985 992
25. M. Munch, C.W. Heegaard, and P.A. Andreasen Interconversions between active, inert and substrate forms of denatured/refolded type-1 plasminogen activator inhibitor Biochim Biophys Acta 1202 1 1993 29 37
26. J. Mottonen, A. Strand, J. Symersky, R.M. Sweet, D.E. Danley, and K.F. Geoghegan Structural basis of latency in plasminogen activator inhibitor-1 Nature 355 6357 1992 270 273
27. K. Aertgeerts, H.L. Debondt, C.J. Deranter, and P.J. Declerck Mechanisms contributing to the conformational and fucntional flexibility of plasminogen activator inhibitor-1 Nat Struct Biol 2 10 1995 891 897
28. H. Nar, M. Bauer, J.M. Stassen, D. Lang, A. Gils, and P.J. Declerck Plasminogen activator inhibitor 1. Structure of the native serpin, comparison to its other conformers and implications for serpin inactivation J Mol Biol 297 3 2000 683 695
29. A.M. Sharp, P.E. Stein, N.S. Pannu, R.W. Carrell, M.B. Berkenpas, and D. Ginsburg The active conformation of plasminogen activator inhibitor 1, a target for drugs to control fibrinolysis and cell adhesion Structure 7 2 1999 111 118
30. T.L. Lindahl, O. Sigurdardottir, and B. Wiman Stability of plasminogen activator inhibitor-1 (PAI-1) Thromb Haemost 62 2 1989 748 751
31. E. Sancho, D.W. Tonge, R.C. Hockney, and N.A. Booth Purification and characterization of active and stable recombinant plasminogen activator inhibitor accumulated at high levels in Escherichia coli Eur J Biochem 224 1 1994 125 134
32. J. Keijer, M. Linders, H. Ehrlich, R.K. Gebbink, and H. Pannekoek Stabilization of plasminogen activator inhibitor type-1 (PAI-1) activity by arginine - Possible implications for the interaction of PAI-1 with vitronectin Fibrinolysis 4 3 1990 153 159
33. J.O. Kvassman, D.A. Lawrence, and J.D. Shore The acid stabilization of plasminogen activator inhibitor-1 depends on protonation of a single group that affects loop insertion into beta-sheet A J Biol Chem 270 46 1995 27942 27947
34. H. Mangs, G.C. Sui, and B. Wiman PAI-1 stability: the role of histidine residues FEBS Lett 475 3 2000 192 196
35. T.J. Stout, H. Graham, D.I. Buckley, and D.J. Matthews Structures of active and latent PAI-1: A possible stabilizing role for chloride ions Biochemistry 39 29 2000 8460 8469
36. D.A. Lawrence, and D.J. Loskutoff Inactivation of plasminogen-activator inhibitor by oxidants Biochemistry 25 21 1986 6351 6355
37. L. Strandberg, D.A. Lawrence, L.B.A. Johansson, and T. Ny The oxidative inactivation of plasminogen activator inhibitor type-1 results from a conformational change in the molecule and does not require the involvement of the P1' methionine J Biol Chem 266 21 1991 13852 13858
38. P.J. Declerck, M. Demol, M.C. Alessi, S. Baudner, E.P. Paques, and K.T. Preissner Purification and characterization of a plasminogen activator inhibitor-1 binding protein from human plasma-Identification as a multimeric form of S-protein (vitronectin) J Biol Chem 263 30 1988 15454 15461
39. J. Boncela, I. Papiewska, I. Fijalkowska, B. Walkowiak, and C.S. Cierniewski Acute phase protein alpha(1)-acid glycoprotein interacts with plasminogen activator inhibitor type 1 and stabilizes its inhibitory activity J Biol Chem 276 38 2001 35305 35311
40. M.B. Berkenpas, D.A. Lawrence, and D. Ginsburg Molecular evolution of plasminogen activator inhibitor-1 functional stability EMBO J 14 13 1995 2969 2977
41. N. Vleugels, A. Gils, S. Mannaerts, I. Knockaert, and P.J. Declerck Evaluation of the mechanism of inactivation of plasminogen activator inhibitor-1 by monoclonal antibodies using a stable variant Fibrinolysis Proteol 12 5 1998 277 282
42. M. Dewilde, S.V. Strelkov, A. Rabijns, and P.J. Declerck High quality structure of cleaved PAI-1-stab J Struct Biol 165 2 2009 126 132
43. A.A. Stoop, E. Eldering, T.R. Dafforn, R.J. Read, and H. Pannekoek Different structural requirements for plasminogen activator inhibitor 1 (PAI-1) during latency transition and proteinase inhibition as evidenced by phage-displayed hypermutated PAI-1 libraries J Mol Biol 305 4 2001 773 783
44. J. Chorostowska-Wynimko, R. Swiercz, E. Skrzypczak-Jankun, A. Wojtowicz, S.H. Selman, and J. Jankun A novel form of the plasminogen activator inhibitor created by cysteine mutations extends its half-life: Relevance to cancer and angiogenesis Mol Cancer Ther 2 1 2003 19 28
45. B. De Taeye, G. Compernolle, M. Dewilde, W. Biesemans, and P.J. Declerck Immobilization of the distal hinge in the labile serpin plasminogen activator inhibitor 1: identification of a transition state with distinct conformational and functional properties J Biol Chem 278 26 2003 23899 23905
46. H.J. Ehrlich, R.K. Gebbink, J. Keijer, M. Linders, K.T. Preissner, and H. Pannekoek Alteration of serpin specificity by a protein cofactor-vitronectin endows plasminogen activator inhibitor-1 with thrombin inhibitory properties J Biol Chem 265 22 1990 13029 13035
47. J. Keijer, M. Linders, J.J. Wegman, H.J. Ehrlich, K. Mertens, and H. Pannekoek On the target specificity of plasminogen activator inhibitor-1 - the role of heparin, vitronectin, and the reactive site Blood 78 5 1991 1254 1261
48. A.R. Rezaie Vitronectin functions as a cofactor for rapid inhibition of activated protein C by plasminogen activator inhibitor-1 - Implications for the mechanism of profibrinolytic action of activated protein C J Biol Chem 276 19 2001 15567 15570
49. R. Carrell, and J. Travis Alpha-1-antitrypsin and the serpins - variation and countervariation Trends Biochem Sci 10 1 1985 20 24
50. P.M. Sherman, D.A. Lawrence, A.Y. Yang, E.T. Vandenberg, D. Paielli, and S.T. Olson Saturation mutagenesis of the plasminogen activator inhibitor-1 reactive center J Biol Chem 267 11 1992 7588 7595
51. P.M. Sherman, D.A. Lawrence, I.M. Verhamme, D. Paielli, J.D. Shore, and D. Ginsburg Identification of tissue-type plasminogen activator-specific plasminogen activator inhibitor-1 mutants - evidence that 2nd sites of interaction contribute to target specificity J Biol Chem 270 16 1995 9301 9306
52. A. Hamsten, B. Wiman, U. Defaire, and M. Blomback Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infraction N Engl J Med 313 25 1985 1557 1563
53. A. Hamsten, U. Defaire, G. Walldius, G. Dahlen, A. Szamosi, and C. Landou Plasminogen activator inhibitor in plasma - risk factor for recurrent myocardial infarction Lancet 2 8549 1987 3 8
54. A.M. Thogersen, J.H. Jansson, K. Boman, T.K. Nilsson, L. Weinehall, and F. Huhtasaari High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women - Evidence for the fibrinolytic system as an independent primary risk factor Circulation 98 21 1998 2241 2247
55. P.M. Ridker, J.E. Manson, J.E. Buring, J.E. Muller, and C.H. Hennekens Circadian variation of acute myocardial infarction and the effect of low-dose aspirin in a randomized trial of physicians Circulation 82 3 1990 897 902
56. F. Andreotti, and C. Kluft Circadian variation of fibrinolytic activity in blood Chronobiol Int 8 5 1991 336 351
57. I. Juhan-Vague, J. Valadier, M.C. Alessi, M.F. Aillaud, J. Ansaldi, and C. Philip-Joet Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis Thromb Haemost 57 1 1987 67 72
58. M.E. Meltzer, T. Lisman, P.G. de Groot, J.C.M. Meijers, S. le Cessie, and C.J.M. Doggen Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1 Blood 116 4 2010 113 121
59. N. Garg, and W.P. Fay Plasminogen activator inhibitor-1 and Restenosis Curr Drug Targets 8 9 2007 1003 1006
60. S. Konstantinides, K. Schafer, and D.J. Loskutoff Do PAI-1 and vitronectin promote or inhibit neointima formation? The exact role of the fibrinolytic system in vascular remodeling remains uncertain Arterioscler Thromb Vasc Biol 22 12 2002 1943 1945
61. B.R. Binder, and J. Mihaly The plasminogen activator inhibitor "paradox" in cancer Immunol Lett 118 2 2008 116 124
62. J. Schneiderman, M.S. Sawdey, M.R. Keeton, G.M. Bordin, E.F. Bernstein, and R.B. Dilley Increased type-1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries Proc Natl Acad Sci U S A 89 15 1992 6998 7002
63. F. Lupu, G.E. Bergonzelli, D.A. Heim, E. Cousin, C.Y. Genton, and F. Bachmann Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries Arterioscler Thromb 13 7 1993 1090 1100
64. W.P. Fay, N. Garg, and M. Sunkar Vascular functions of the plasminogen activation system Arterioscler Thromb Vasc Biol 27 6 2007 1231 1237
65. M.H. Prins, and J. Hirsh A critical review of the evidence supporting a relationship between impaired fibrinolytic activity and venous thromboembolism Arch Intern Med 151 9 1991 1721 1731
66. I. Juhan-Vague, S.D.M. Pyke, M.C. Alessi, J. Jespersen, F. Haverkate, and S.G. Thompson Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris Circulation 94 9 1996 2057 2063
67. A.R. Folsom, N. Aleksik, E. Park, V. Salomaa, H. Juneja, and K.K. Wu Prospective study of fibrinolytic factors and incident coronary heart disease - The Atherosclerosis Risk in Communities (ARIC) Study Arterioscler Thromb Vasc Biol 21 4 2001 611 617
68. M.C. Alessi, F. Peiretti, P. Morange, M. Henry, G. Nalbone, and I. JuhanVague Production of plasminogen activator inhibitor 1 by human adipose tissue - Possible link between visceral fat accumulation and vascular disease Diabetes 46 5 1997 860 867
69. K. Schafer, K. Fujisawa, S. Konstantinides, and D.J. Loskutoff Disruption of the plasminogen activator inhibitor-1 gene reduces the adiposity and improves the metabolic profile of genetically obese and diabetic ob/ob mice FASEB J 15 8 2001 1840 1842
70. T.K. Nordt, H. Sawa, S. Fujii, C. Bode, and B.E. Sobel Augmentation of arterial endothelial cell expression of the plasminogen activator inhibitor type-1 (PAI-1) gene by proinsulin and insulin in vivo J Mol Cell Cardiol 30 8 1998 1535 1543
71. S.J. Dawson, B. Wiman, A. Hamsten, F. Green, S. Humphries, and A.M. Henney The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells J Biol Chem 268 15 1993 10739 10745
72. Ringelstein M, Jung A, Berger K, Stoll M, Madlener K, Klötzsch C, et al. Promotor polymorphisms of plasminogen activator inhibitor-1 and other thrombophilic genotypes in cerebral venous thrombosis: a case-control study in adults. J Neurol in press., 10.1007/s00415-012-6477-7.
73. A.E. Tsantes, G.K. Nikolopoulos, P.G. Bagos, S. Bonovas, P. Kopterides, and G. Vaiopoulos The effect of the plasminogen activator inhibitor-1 4G/5G polymorphism on the thrombotic risk Thromb Res 122 6 2008 736 742
74. L.A. Erickson, G.J. Fici, J.E. Lund, T.P. Boyle, H.G. Polites, and K.R. Marotti Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor-1 gene Nature 346 6279 1990 74 76
75. M. Eren, C.A. Painter, J.B. Atkinson, P.J. Declerck, and D.E. Vaughan Age-dependent spontaneous coronary arterial thrombosis in transgenic mice that express a stable form of human plasminogen activator inhibitor-1 Circulation 106 4 2002 491 496
76. P. Carmeliet, J.M. Stassen, L. Schoonjans, B. Ream, J.J. Vandenoord, and M. Demol Plasminogen activator inhibitor-1 gene deficient mice. II. Effects on hemostasis, thrombosis and thrombolysis J Clin Invest 92 6 1993 2756 2760
77. R.R. Schleef, D.L. Higgins, E. Pillemer, and L.J. Levitt Bleeding diathesis due to decreased fucntional activity of type 1 plasminogen activator inhibitor J Clin Invest 83 5 1989 1747 1752
78. J. Dieval, G. Nguyen, S. Gross, J. Delobel, and E.K.O. Kruithof A lifelong bleeding disorder associated with a deficiency of plasminogen activator inhibitor type-1 Blood 77 3 1991 528 532
79. M.H. Lee, E. Vosburgh, K. Anderson, and J. McDonagh Deficiency of plasma plasminogen activator inhibitor-1 results in hyperfibrinolytic bleeding Blood 81 9 1993 2357 2362
80. W.P. Fay, A.C. Parker, L.R. Condrey, and A.D. Shapiro Human plasminogen activator inhibitor-1 (PAI-1) deficiency: Characterization of a large kindred with a null mutation in the PAI-1 gene Blood 90 1 1997 204 208
81. R. Mehta, and A.D. Shapiro Plasminogen activator inhibitor type 1 deficiency Haemophilia 14 6 2008 1255 1260
82. Z.Y. Zhang, Z.Y. Wang, N.Z. Dong, X. Bai, W. Zhang, and C.G. Ruan A case of deficiency of plasma plasminogen activator inhibitor-1 related to Ala15Thr mutation in its signal peptide Blood Coagul Fibrinolysis 16 2005 79 84 [00001721-200501000-00013 [pii]]
83. J. Halamkova, I. Kiss, Z. Pavlovsky, J. Jarkovsky, J. Tomasek, and S. Tucek Clinical relevance of uPA, uPAR, PAI 1 and PAI 2 tissue expression and plasma PAI 1 level in colorectal carcinoma patients Hepatogastroenterology 58 112 2011 1918 1925
84. S. Komiyama, D. Aoki, E. Saitoh, M. Komiyama, and Y. Udagawa Biological significance of plasminogen activator inhibitor-1 expression in ovarian clear cell adenocarcinoma Eur J Gynaecol Oncol 32 6 2011 611 614
85. M.K. Durand, J.S. Bodker, A. Christensen, D.M. Dupont, M. Hansen, and J.K. Jensen Plasminogen activator inhibitor-1 and tumour growth, invasion, and metastasis Thromb Haemost 91 3 2004 438 449
86. L. Devy, S. Blacher, C. Grignet-Debrus, K. Bajou, R. Masson, and R.D. Gerard The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent FASEB J 16 2 2002 147 154
87. K. Bajou, C. Maillard, M. Jost, R.H. Lijnen, A. Gils, and P. Declerck Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth Oncogene 23 41 2004 6986 6990
88. D.J. Schneider, Y. Chen, and B.E. Sobel The effect of plasminogen activator inhibitor type 1 on apoptosis Thromb Haemost 100 6 2008 1037 1040
89. H.R. Lijnen Pleiotropic functions of plasminogen activator inhibitor-1 J Thromb Haemost 3 1 2005 35 45
90. M. Cesari, M. Pahor, and R.A. Incalzi Plasminogen Activator Inhibitor-1 (PAI-1): A Key Factor Linking Fibrinolysis and Age-Related Subclinical and Clinical Conditions Cardiovasc Ther 28 5 2010 e72 e91
91. H.R. Lijnen, and I. Juhan-Vague The fibrinolytic system and obesity Thromb Haemost 88 5 2002 882
92. P.E. Morange, H.R. Lijnen, M.C. Alessi, F. Kopp, D. Collen, and I. Juhan-Vague Influence of PAI-1 on adipose tissue growth and metabolic parameters in a murine model of diet-induced obesity Arterioscler Thromb Vasc Biol 20 4 2000 1150 1154
93. H.R. Lijnen, E. Maquoi, P. Morange, G. Voros, B. Van Hoef, and F. Kopp Nutritionally induced obesity is attenuated in transgenic mice overexpressing plasminogen activator inhibitor-1 Arterioscler Thromb Vasc Biol 23 1 2003 78 84
94. H.R. Lijnen Effect of plasminogen activator inhibitor-l deficiency on nutritional ly-ind uced obesity in mice Thromb Haemost 93 5 2005 816 819
95. M.C. Alessi, and I. Juhan-Vague PAI-1 and the metabolic syndrome - Links, causes, and consequences Arterioscler Thromb Vasc Biol 26 10 2006 2200 2207
96. M. Alessi, V. Nicaud, I. Scroyen, C. Lange, N. Saut, and F. Fumeron Association of vitronectin and plasminogen activator inhibitor-1 levels with the risk of metabolic syndrome and type 2 diabetes mellitus. Results from the D.E.S.I.R. prospective cohort Thromb Haemost 106 3 2011 416 422
97. L.S. Nielsen, P.A. Andreasen, J. Grondahlhansen, J.Y. Huang, P. Kristensen, and K. Dano Monoclonal antibodies to human 54,000 molecular weight plasminogen activator inhibitor from fibrosarcoma cells-inhibitor neutralization and one-step affinity purification Thromb Haemost 55 2 1986 206 212
98. J. Keijer, M. Linders, A.J. Vanzonneveld, H.J. Ehrlich, J.P. Deboer, and H. Pannekoek The interaction of plasminogen activator inhibitor-1 with plasminogen activators (tissue-type and urokinase-type) and fibrin - Localization of interaction sites and physiological relevance Blood 78 2 1991 401 409
99. A.P. Bijnens, A. Gils, J.M. Stassen, A.A. Komissarov, I. Knockaert, and E. Brouwers The distal hinge of the reactive site loop and its proximity - A target to modulate plasminogen activator inhibitor-1 activity J Biol Chem 276 48 2001 44912 44918
100. A.M. Perrie, I.R. Macgregor, and N.A. Booth Definition of epitopes within plasminogen activator inhibitor type-1 (PAI-1) using multiple peptide synthesis Fibrinolysis 7 4 1993 257 263
101. T.H. Ngo, M.F. Hoylaerts, I. Knockaert, E. Brouwers, and P.J. Declerck Identification of a target site in plasminogen activator inhibitor-1 that allows neutralization of its inhibitory properties concomitant with an allosteric up-regulation of its antiadhesive properties J Biol Chem 276 28 2001 26243 26248
102. A.P. Bijnens, A. Gils, I. Knockaert, J.M. Stassen, and P.J. Declerck Importance of the hinge region between alpha-helix F and the main part of serpins, based upon identification of the epitope of plasminogen activator inhibitor type 1 neutralizing antibodies J Biol Chem 275 9 2000 6375 6380
103. T. Wind, M.A. Jensen, and P.A. Andreasen Epitope mapping for four monoclonal antibodies against human plasminogen activator inhibitor type-1 - Implications for antibody-mediated PAI-1-neutralization and vitronectin-binding Eur J Biochem 268 4 2001 1095 1106
104. A.A. Stoop, L. Jespers, I. Lasters, E. Eldering, and H. Pannekoek High-density mutagenesis by combined DMA shuffling and phage display to assign essential amino acid residues in protein-protein interactions: Application to study structure-function of plasminogen activation inhibitor 1 (PAI-I) J Mol Biol 301 5 2000 1135 1147
105. B. Van De Craen, I. Scroyen, R. Abdelnabi, E. Brouwers, H.R. Lijnen, and P.J. Declerck Characterization of a panel of monoclonal antibodies toward mouse PAI-1 that exert a significant profibrinolytic effect in vivo Thromb Res 128 1 2011 68 76
106. D. Naessens, A. Gils, G. Compernolle, and P.J. Declerck Elucidation of a novel epitope of a substrate-inducing monoclonal antibody against the serpin PAI-1 J Thromb Haemost 1 5 2003 1028 1033
107. S. Debrock, L. Sironi, and P.J. Declerck Cloning of a single-chain variable fragment (scFv) switching active plasminogen activator inhibitor-1 to substrate Gene 189 1 1997 83 88
108. K. Verbeke, A. Gils, and P.J. Declerck Cloning and paratope analysis of an antibody fragment, a rational approach for the design of a PAI-1 inhibitor J Thromb Haemost 2 2 2004 289 297
109. K. Verbeke, A. Gils, and P.J. Declerck Inhibition of plasminogen activator inhibitor-1: antibody fragments and their unique sequences as a tool for the development of profibrinolytic drugs J Thromb Haemost 2 2 2004 298 305
110. B. De Taeye, G. Compernolle, and P.J. Declerck Site-directed targeting of plasminogen activator inhibitor-1 as an example for a novel approach in rational drug design J Biol Chem 279 19 2004 20447 20450 10.1074/jbc.M401971200
111. D. Naessens, A. Gils, G. Compernolle, and P.J. Declerck Elucidation of the epitope of a latency-inducing antibody: identification of a new molecular target for PAI-1 inhibition Thromb Haemost 90 1 2003 52 58
112. N.V. Gorlatova, H. Elokdah, K. Fan, D.L. Crandall, and D.A. Lawrence Mapping of a conformational epitope on plasminogen activator inhibitor-1 by random mutagenesis - Implications for serpin function J Biol Chem 278 18 2003 16329 16335
113. T.H. Ngo, Y. Zhou, J.M. Stassen, and P.J. Declerck Importance of N-terminal residues in plasminogen activator inhibitor 1 on its antibody induced latency transition Thromb Haemost 88 2 2002 288 293
114. D.M. Dupont, G.E. Blouse, M. Hansen, L. Mathiasen, S. Kjelgaard, and J.K. Jensen Evidence for a pre-latent form of the serpin plasminogen activator inhibitor-1 with a detached beta-strand 1C J Biol Chem 281 47 2006 36071 36081
115. D.T. Eitzman, W.P. Fay, D.A. Lawrence, A.M. Francischmura, J.D. Shore, and S.T. Olson Peptide-mediated inactivation of recombinant and platelet plasminogen activator inhibitor-1 in vitro J Clin Invest 95 5 1995 2416 2420
116. Y.F. Xue, P. Bjorquist, T. Inghardt, M. Linschoten, D. Musil, and L. Sjolin Interfering with the inhibitory mechanism of serpins: crystal structure of a complex formed between cleaved plasminogen activator inhibitor type 1 and a reactive-centre loop peptide Structure 6 5 1998 627 636
117. S. D'Amico, J. Martial, and I. Struman A peptide mimicking the C-terminal part of the reactive center loop induces the transition to the latent form of plasminogen activator inhibitor type-1 FEBS Lett 586 6 2012 686 692
118. T. Chavakis, R.A. Pixley, I. Isordia-Salas, R.W. Colman, and K.T. Preissner A novel antithrombotic role for high molecular weight kininogen as inhibitor of plasminogen activator inhibitor-1 function J Biol Chem 277 36 2002 32677 32682
119. J. Bryans, P. Charlton, I. ChicarelliRobinson, M. Collins, R. Faint, and C. Latham Inhibition of plasminogen activator inhibitor-1 activity by two diketopiperazines, XR330 and XR334 produced by Streptomyces sp J Antibiot 49 10 1996 1014 1021
120. P.A. Charlton, R.W. Faint, F. Bent, J. Bryans, I. ChicarelliRobinson, and I. Mackie Evaluation of a low molecular weight modulator of human plasminogen activator inhibitor-1 activity Thromb Haemost 75 5 1996 808 815
121. P. Charlton, R. Faint, C. Barnes, F. Bent, A. Folkes, and D. Templeton XR5118, a novel modulator of plasminogen activator inhibitor-1 (PAI-1), increases endogenous tPA activity in the rat Fibrinolysis Proteol 11 1 1997 51 56
122. A. Folkes, M.B. Roe, S. Sohal, J. Golec, R. Faint, and T. Brooks Synthesis and in vitro evaluation of a series of diketopiperazine inhibitors of plasminogen activator inhibitor-1 Bioorg Med Chem Lett 11 19 2001 2589 2592
123. P.W. Friederich, M. Levi, B.J. Biemond, P. Charlton, D. Templeton, and A.J. vanZonneveld Novel low-molecular-weight inhibitor of PAI-1 (XR5118) promotes endogenous fibrinolysis and reduces postthrombolysis thrombus growth in rabbits Circulation 96 3 1997 916 921
124. P. Bjorquist, J. Ehnebom, T. Inghardt, L. Hansson, M. Lindberg, and M. Linschoten Identification of the binding site for a low-molecular-weight inhibitor of plasminogen activator inhibitor type 1 by site-directed mutagenesis Biochemistry 37 5 1998 1227 1234
125. A. Gils, J.M. Stassen, H. Nar, J.T. Kley, W. Wienen, and U.J. Ries Characterization and comparative evaluation of a novel PAI-1 inhibitor Thromb Haemost 88 1 2002 137 143
126. A. Gils, and P.J. Declerck Modulation of plasminogen activator inhibitor 1 by Triton X-100 - Identification of two consecutive conformational transitions Thromb Haemost 80 2 1998 286 291
127. H. Elokdah, M. Abou-Gharbia, J.K. Hennan, G. McFarlane, C.P. Mugford, and G. Krishnamurthy Tiplaxtinin, a novel, orally efficacious inhibitor of plasminogen activator inhibitor-1: Design, synthesis, and preclinical characterization J Med Chem 47 14 2004 3491 3494
128. H.R. Lijnen, M.C. Alessi, L. Frederix, D. Collen, and I. Juhan-Vague Tiplaxtinin impairs nutritionally induced obesity in mice Thromb Haemost 96 6 2006 731 737
129. D.L. Crandall, E.M. Quinet, S. Ayachi, A.L. Hreha, C.E. Leik, and D.A. Savio Modulation of adipose tissue development by pharmacological inhibition of PAI-1 Arterioscler Thromb Vasc Biol 26 10 2006 2209 2215
130. S. Baxi, D.L. Crandall, T.R. Meier, S. Wrobleski, A. Hawley, and D. Farris Dose-dependent thrombus resolution due to oral plaminogen activator inhibitor (PAI)-I inhibition with tiplaxtinin in a rat stenosis model of venous thrombosis Thromb Haemost 99 4 2008 749 758
131. S. Lee, M. Eren, D. Vaughan, R. Schleimer, and S. Cho A PAI-1 inhibitor reduces airway remodeling in a murine model of chronic asthma Am J Respir Cell Mol Biol 46 6 2012 842 846
132. A. Rupin, R. Gaertner, P. Mennecier, I. Richard, A. Benoist, and G. De Nanteuil S35225 is a direct inhibitor of Plasminogen Activator Inhibitor type-1 activity in the blood Thromb Res 122 2 2008 265 270
133. N.V. Gorlatova, J.M. Tale, H. Elokdah, D.H. Li, K. Fan's, and M. Warnock Mechanism of inactivation of plasminogen activator inhibitor-1 by a small molecule inhibitory J Biol Chem 282 12 2007 9288 9296
134. S. Gardell, J. Krueger, T. Antrilli, H. Elokdah, S. Mayer, and S. Orcutt Neutralization of plasminogen activator inhibitor I (PAI-1) by the synthetic antagonist PAI-749 via a dual mechanism of action Mol Pharmacol 72 4 2007 897 906
135. A. Lucking, A. Visvanathan, H. Philippou, S. Fraser, P. Grant, and T. Connolly Effect of the small molecule plasminogen activator inhibitor-1 (PAI-1) inhibitor, PAI-749, in clinical models of fibrinolysis J Thromb Haemost 8 6 2010 1333 1339
136. J.M. Cale, S.H. Li, M. Warnock, E.J. Su, P.R. North, and K.L. Sanders Characterization of a Novel Class of Polyphenolic Inhibitors of Plasminogen Activator Inhibitor-1 J Biol Chem 285 11 2010 7892 7902
137. Y. Izuhara, N. Yamaoka, H. Kodama, T. Dan, S. Takizawa, and N. Hirayama A novel inhibitor of plasminogen activator inhibitor-1 provides antithrombotic benefits devoid of bleeding effect in nonhuman primates J Cereb Blood Flow Metab 30 5 2010 904 912
138. W. Huang, P. Vayalil, T. Miyata, J. Hagood, and R. Liu Therapeutic value of small molecule inhibitor to plasminogen activator inhibitor-1 for lung fibrosis Am J Respir Cell Mol Biol 46 1 2012 87 95
139. G. Derosa, A. D'Angelo, P.D. Ragonesi, L. Ciccarelli, M.N. Piccinni, and F. Pricolo Effects of rosiglitazone and pioglitazone combined with metformin on the prothrombotic state of patients with type 2 diabetes mellitus and metabolic syndrome J Int Med Res 34 5 2006 545 555
140. S. Fujii, H. Sawa, and B.E. Sobel Inhibition of endothelial cell expression of plasminogen activator inhibitor type-1 by gemfibrozil Thromb Haemost 70 4 1993 642 647
141. B. Vinogradsky, S.P. Bell, J. WoodcockMitchell, A. Ohtani, and S. Fujii A new butadiene derivative, T-686, inhibits plasminogen activator inhibitor type-1 production in vitro by cultured human vascular endothelial cells and development of atherosclerotic lesions in vivo in rabbits Thromb Res 85 4 1997 305 314
142. Z. Pawlowska, E. Chabielska, A. Kobylanska, A. Maciaszek, M. Swiatkowska, and W. Buczko Regulation of PAI-1 concentration in platelets by systemic administration of antisense oligonucleotides to rats Thromb Haemost 85 6 2001 1086 1089
143. Q.S. Jiang, and S.Q. Wang Design and screening of antisense oligodeoxynucleotides against PAI-1 mRNA in endothelial cells in vitro Acta Pharmacol Sin 27 8 2006 1018 1023
144. M. Izumi, K.M. Yamada, and M. Hayashi Vitronectin exists in two structurally and functionally distinct forms in human plasma Biochim Biophys Acta 990 2 1989 101 108
145. A.A. Stoop, F. Lupu, and H. Pannekoek Colocalization of thrombin, PAI-1, and vitronectin in the atherosclerotic vessel wall: A potential regulatory mechanism of thrombin activity by PAI-1/vitronectin complexes Arterioscler Thromb Vasc Biol 20 4 2000 1143 1149
146. M.C. Naski, D.A. Lawrence, D.F. Mosher, T.J. Podor, and D. Ginsburg Kinetics of inactivation of alpha-thrombin by plasminogen activator inhibitor-1. Comparison of the effects of native and urea-treated forms of vitronectin J Biol Chem 268 17 1993 12367 12372
147. H.J. Ehrlich, R.K. Gebbink, K.T. Preissner, J. Keijer, N.L. Esmon, and K. Mertens Thrombin neutralizes plasminogen activator inhibitor 1 (PAI-1) that is complexed with vitronectin in the endothelial cell matrix J Cell Biol 115 6 1991 1773 1781
148. S. Stefansson, G.A. McMahon, E. Petitclerc, and D.A. Lawrence Plasminogen activator inhibitor-1 in tumor growth, angiogenesis and vascular remodeling Curr Pharm Des 9 19 2003 1545 1564
149. C.M. Blake, B.A. Sullenger, D.A. Lawrence, and Y.M. Fortenberry Antimetastatic potential of PAI-1-specific RNA aptamers Oligonucleotides 19 2 2009 117 128
150. L. Kjoller, P.M. Martensen, L. SottrupJensen, J. Justesen, K.W. Rodenburg, and P.A. Andreasen Conformational changes of the reactive-centre loop and beta-strand 5A accompany temperature-dependent inhibitor-substrate transition of plasminogen-activator inhibitor 1 Eur J Biochem 241 1 1996 38 46
151. M.C. Alessi, P.J. Declerck, M. Demol, L. Nelles, and D. Collen Purification and characterization of natural and recombinant human plasminogen activator inhibitor-1 (PAI-1) Eur J Biochem 175 3 1988 531 540
152. A. Gils, K.E. Pedersen, P. Skottrup, A. Christensen, D. Naessens, and J. Deinum Biochemical importance of glycosylation of plasminogen activator inhibitor-I Thromb Haemost 90 2 2003 206 217
153. K.W. Rodenburg, L. Kjoller, H.H. Petersen, and P.A. Andreasen Binding of urokinase-type plasminogen activator plasminogen activator inhibitor-1 complex to the endocytosis receptors alpha(2)-macroglobulin receptor low-density lipoprotein receptor-related protein and very-low-density lipoprotein receptor involves basic residues in the inhibitor Biochem J 329 Pt 1 1998 55 63
154. A. Gils, I. Knockaert, and P.J. Declerck Substrate behavior of plasminogen activator inhibitor-1 is not associated with a lack of insertion of the reactive site loop Biochemistry 35 23 1996 7474 7481
155. D. Lawrence, L. Strandberg, T. Grundstrom, and T. Ny Purification of active human plasminogen activator inhibitor-1 from Escherichia coli-comparison with natural and recombinant forms purified from eukaryotic cells Eur J Biochem 186 3 1989 523 533
156. A. Gils, I. Knockaert, E. Brouwers, and P.J. Declerck Glycosylation dependent conformational transitions in plasminogen activator inhihitor-1: evidence for the presence of two active conformations Fibrinolysis Proteol 14 1 2000 58 64
157. R. Serrano, J. Barrenetxe, J. Orbe, J.A. Rodriguez, N. Gallardo, and C. Martinez Tissue-specific PAI-1 gene expression and glycosylation pattern in insulin-resistant old rats Am J Physiol Regul Integr Comp Physiol 297 5 2009 R1563 R1569
158. H. Brogren, C. Sihlbom, K. Wallmark, M. Lonn, J. Deinum, and L. Karlsson Heterogeneous glycosylation patterns of human PAI-1 may reveal its cellular origin Thromb Res 122 2 2008 271 281
159. B. Van De Craen, I. Scroyen, C. Vranckx, G. Compernolle, H.R. Lijnen, and P.J. Declerck Maximal PAI-1 inhibition in vivo requires neutralizing antibodies that recognize and inhibit glycosylated PAI-1 Thromb Res 129 4 2012 126 133
160. J. Mestas, and C.C.W. Hughes Of mice and not men: Differences between mouse and human immunology J Immunol 172 5 2004 2731 2738
161. H.R. Lijnen, B. Vanhoef, V. Beelen, and D. Collen Characterization of the murine plasma fibrinolytic system Eur J Biochem 224 3 1994 863 871
162. Z. Xu, R.D. Balsara, N.V. Gorlatova, D.A. Lawrence, F.J. Castellino, and V.A. Ploplis Conservation of critical functional domains in murine plasminogen activator inhibitor-1 J Biol Chem 279 17 2004 17914 17920
163. A. Gils, L.M. Meissenheimer, G. Compernolle, and P.J. Declerck Species-dependent molecular drug targets in plasminogen activator inhibitor-1 (PAI-1) Thromb Haemost 102 3 2009 609 610
164. M. Dewilde, B. Van De Craen, G. Compernolle, J.B. Madsen, S. Strelkov, and A. Gils Subtle structural differences between human and mouse PAI-1 reveal the basis for biochemical differences J Struct Biol 171 1 2010 95 101
165. N. Vleugels, J. Leys, I. Knockaert, and P.J. Declerck Effect of stabilizing versus destabilizing interactions on plasminogen activator inhibitor-1 Thromb Haemost 84 5 2000 871 875